References

1. Martin S, Jung R. Gastrointestinal infections and enterotoxigenic poisonings. In: DiPiro JT, Talbert RL, Yee GC, et al., eds. Pharmacotherapy: A Pathophysiologic Approach, 6th ed. New York: McGraw-Hill, 2005:2035-2053.

2. Kotloff KL, Winickoff JP, Ivanoff B, et al. Global burden of Shigella infections: Implications for vaccine development and implementation of control strategies. Bull World Health Organ 1999;77:651-666.

3. DuPont HL, Levine MM, Hornick RB, Formal SB. Inoculum size in shigellosis and implications for expected mode of transmission. J Infect Dis 1989;159:1126-1128.

4. Sansonetti PJ. Rupture, invasion and inflammatory destruction of the intestinal barrier by Shigella, making sense of prokaryote-eukaryote cross-talks. FEMS Microbiol Rev 2001;25:3-14.

5. The choice of antibacterial drugs. Med Lett Drugs Ther 2001;43: 69-78.

6. Taylor DN, McKenzie R, Durbin A, et al. Rifaximin, a nonabsorbed oral antibiotic, prevents shigellosis after experimental challenge. Clin Infect Dis 2006;42:1283-1288.

7. Ackers ML, Puhr ND, Tauxe RV, Mintz ED. Laboratory-based surveillance of Salmonella serotype Typhi infections in the United States: Antimicrobial resistance on the rise. JAMA 2000;283:2668-2673.

8. Butler T, Frenck RW, Johnson RB, Khakhria R. In vitro effects of azithromycin on Salmonella typhi: Early inhibition by concentrations less than the MIC and reduction of MIC by alkaline pH and small inocula. J Antimicrob Chemother 2001;47:455-458.

9. ACIP revises typhoid immunization recommendations. Am Fam Physician 1995;51:969-970.

10. Skirrow MB. In: Blaser MJ, Smith PD, Ravdin J, eds. Infections of the Gastrointestinal Tract, 2nd ed. Philadelphia: Lippincott-Raven, 2002:825-848.

11. Paton JC, Paton AW. Pathogenesis and diagnosis of Shiga toxin-producing Escherichia coli infections. Clin Microbiol Rev 1998;11:450-479.

12. Sack DA, Sack RB, Nair GB, Siddique AK. Cholera. Lancet 2004;363: 223-233.

13. Blake PA, Allegra DT, Snyder JD, et al. Cholera—a possible endemic focus in the United States. N Engl J Med 1980;302:305-309.

14. Faruque SM, Chowdhury N, Kamruzzaman M, et al. Reemergence of epidemic Vibrio cholerae O139, Bangladesh. Emerg Infect Dis 2003;9:1116-1122.

15. Glass RI, Holmgren J, Haley CE, et al. Predisposition for cholera of individuals with O blood group. Possible evolutionary significance. Am J Epidemiol 1985;121:791-796.

16. Sack DA, Tacket CO, Cohen MB, et al. Validation of a volunteer model of cholera with frozen bacteria as the challenge. Infect Immun 1998;66:1968-1972.

17. Field M, Fromm D, al-Awqati Q, Greenough WB 3rd. Effect of cholera enterotoxin on ion transport across isolated ileal mucosa. J Clin Invest 1972;51:796-804.

18. Zaman K, Yunus M, Rahman A, et al. Efficacy of a packaged rice oral rehydration solution among children with cholera and cholera-like illness. Acta Paediatr 2001;90:505-510.

19. Cohen MB, Giannella RA, Bean J, et al. Randomized, controlled human challenge study of the safety, immunogenicity, and protective efficacy of a single dose of Peru-15, a live attenuated oral cholera vaccine. Infect Immun 2002;70:1965-1970.

20. Holmgren J, Clemens J, Sack DA, Svennerholm AM. New cholera vaccines. Vaccine 1989;7:94-96.

21. Tacket CO, Cohen MB, Wasserman SS, et al. Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El For Inaba three months after vaccination. Infect Immun 1999;67:6341-6345.

22. Tacket CO, Kotloff KL, Losonsky G, et al. Volunteer studies investigating the safety and efficacy of live oral El For Vibrio cholerae O1 vaccine strain CVD 111. Am J Trop Med Hyg 1997;56:533-537.

23. Tacket CO, Losonsky G, Nataro JP, et al. Initial clinical studies of CVD 112 Vibrio cholerae O139 live oral vaccine: Safety and efficacy against experimental challenge. J Infect Dis 1995;172:883-886.

24. Trach DD, Clemens JD, Ke NT, et al. Field trial of a locally produced, killed, oral cholera vaccine in Vietnam. Lancet 1997;349:231-235.

25. Okhuysen PC. Current concepts in travelers' diarrhea: Epidemiology, antimicrobial resistance and treatment. Curr Opin Infect Dis 2005;18:522-526.

26. Chapin AR, Carpenter CM, Dudley WC, et al. Prevalence of norovirus among visitors from the United States to Mexico and Guatemala who experience traveler's diarrhea. J Clin Microbiol 2005;43:1112-1117.

27. Huang DB, Sanchez AP, Triana E, et al. United States male students who heavily consume alcohol in Mexico are at greater risk of travelers' diarrhea than their female counterparts. J Travel Med 2004;11:143-145.

28. Bartlett JG. Clostridium difficile: History of its role as an enteric pathogen and the current state of knowledge about the organism. Clin Infect Dis 1994;18(Suppl 4):S265-S272.

29. Wistrom J, Norrby SR, Myhre EB, et al. Frequency of antibiotic-associated diarrhoea in 2462 antibiotic-treated hospitalized patients: A prospective study. J Antimicrob Chemother 2001;47:43-50.

30. Gaynes R, Rimland D, Killum E, et al. Outbreak of Clostridium difficile infection in a long-term care facility: Association with gatifloxacin use. Clin Infect Dis 2004;38:640-645.

31. Pepin J, Saheb N, Coulombe MA, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: A cohort study during an epidemic in Quebec. Clin Infect Dis 2005;41:1254-1260.

32. Bignardi GE. Risk factors for Clostridium difficile infection. J Hosp Infect 1998;40:1-15.

33. Dial S, Delaney JA, Barkun AN, Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 2005;294:2989-2995.

34. Apisarnthanarak A, Razavi B, Mundy LM. Adjunctive intracolonic vancomycin for severe Clostridium difficile colitis: Case series and review of the literature. Clin Infect Dis 2002;35:690-696.

35. Chen XM, Keithly JS, Paya CV, LaRusso NF. Cryptosporidiosis. N Engl J Med 2002;346:1723-1731.

36. Smith HV, Corcoran GD. New drugs and treatment for cryptosporidiosis. Curr Opin Infect Dis 2004;17:557-564.

37. White AC. Nitazoxanide: A new broad spectrum antiparasitic agent. Expert Rev Anti Infect Ther 2004;2:43-50.

38. Mead PS, Slutsker L, Dietz V, et al. Food-related illness and death in the United States. Emerg Infect Dis 1999;5:607-625.

39. Mounts AW, Holman RC, Clarke MJ, et al. Trends in hospitalizations associated with gastroenteritis among adults in the United States, 1979-1995. Epidemiol Infect 1999;123:1-8.

40. Clark B, McKendrick M. A review of viral gastroenteritis. Curr Opin Infect Dis 2004;17:461-469.

41. Parashar UD, Hummelman EG, Bresee JS, et al. Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis 2003;9:565-572.

42. Wilhelmi I, Roman E, Sanchez-Fauquier A. Viruses causing gastroenteritis. Clin Microbiol Infect 2003;9:247-262.

43. Vesikari T, Matson DO, Dennehy P, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006;354:23-33.

Blood Pressure Health

Blood Pressure Health

Your heart pumps blood throughout your body using a network of tubing called arteries and capillaries which return the blood back to your heart via your veins. Blood pressure is the force of the blood pushing against the walls of your arteries as your heart beats.Learn more...

Get My Free Ebook


Post a comment